Francesca Buontempo
Overview
Explore the profile of Francesca Buontempo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buontempo F, Orsini E, Zironi I, Isolan L, Cappellini A, Rapino S, et al.
PLoS One
. 2018 Jun;
13(6):e0199312.
PMID: 29958291
Radiation therapy is a useful and standard tumor treatment strategy. Despite recent advances in delivery of ionizing radiation, survival rates for some cancer patients are still low because of recurrence...
2.
Salucci S, Burattini S, Buontempo F, Orsini E, Furiassi L, Mari M, et al.
Eur J Histochem
. 2018 Jun;
62(2):2881.
PMID: 29943949
Marine organisms such as corals, sponges and tunicates produce active molecules which could represent a valid starting point for new drug development processes. Among the various structural classes, the attention...
3.
Martelli A, Buontempo F, McCubrey J
Clin Sci (Lond)
. 2018 Mar;
132(5):543-568.
PMID: 29523752
Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. mTORC1 and mTORC2...
4.
Salucci S, Burattini S, Buontempo F, Martelli A, Falcieri E, Battistelli M
Eur J Histochem
. 2017 Oct;
61(3):2784.
PMID: 29046052
Skin cells can respond to UVB-induced damage either by tolerating it, or restoring it through antioxidant activation and DNA repair mechanisms or, ultimately, undergoing programmed cell death, when damage is...
5.
Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata J, Bertaina A, et al.
J Cell Physiol
. 2017 Aug;
233(3):1796-1811.
PMID: 28777460
Despite remarkable progress in polychemotherapy protocols, pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains fatal in around 20% of cases. Hence, novel targeted therapies are needed for patients with poor prognosis....
6.
Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, et al.
J Hematol Oncol
. 2016 Oct;
9(1):114.
PMID: 27776559
Background: Although in recent years, the introduction of novel chemotherapy protocols has improved the outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a foremost...
7.
Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, et al.
Oncotarget
. 2015 Nov;
7(2):1323-40.
PMID: 26593250
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of bortezomib alone has been reported. A...
8.
Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, et al.
Biochim Biophys Acta
. 2015 Sep;
1863(3):449-463.
PMID: 26334291
The bone marrow (BM) microenvironment regulates the properties of healthy hematopoietic stem cells (HSCs) localized in specific niches. Two distinct microenvironmental niches have been identified in the BM, the "osteoblastic...
9.
Salamanna F, Pagani S, Maglio M, Borsari V, Giavaresi G, Martelli A, et al.
Histol Histopathol
. 2015 Aug;
31(1):83-93.
PMID: 26254457
To reduce the burden of bone metastases, the pathophysiology of the metastatic niche should be elucidated and targeted. The aim of the present study was to assess the effect of...
10.
Salucci S, Burattini S, Battistelli M, Buontempo F, Canonico B, Martelli A, et al.
J Dermatol Sci
. 2015 Jul;
80(1):61-8.
PMID: 26166167
Background: Phenolic compounds, the biggest group of natural antioxidants, have attracted much attention due to their known and wide-ranging biological activities, as well as to their health effects. In particular,...